Analyst Color

Solar and wind operator TerraForm Power Inc (NASDAQ: TERP) reported second-quarter results Monday that convinced Oppenheimer to turn bullish on the stock. The Analyst Oppenheimer's Colin Rusch upgraded TerraForm Power from Perform to Outperform with a new $14 price target. The Thesis...

Columbia Sportswear Company (NASDAQ: COLM) shares are up over 26 percent year-to-date, but the company's brand portfolio is underappreciated, according to Cowen.  The Analyst  Cowen analyst John Kernan upgraded Columbia Sportswear from Market Perform rating to Outperform and...

Following the 90-percent year-to-date appreciation in Intercept Pharmaceutical, Inc. (NASDAQ: ICPT) shares, RBC Capital Markets considers the stock's risk-reward to be balanced.  The Analyst RBC Capital Markets analyst Brian Abrahams downgraded Intercept from Outperform to Sector...

The incredible growth of NVIDIA Corporation (NASDAQ: NVDA) coupled with its stock’s lofty market valuation has created plenty of Nvidia bulls and bears on Wall Street. On Wednesday, one prominent bear made a complete 180-degree turn. The Analyst Wells Fargo analyst Aaron Rakers issued a...

The bearish case for Advance Auto Parts, Inc. (NYSE: AAP) has come to an end after the company's second-quarter results came in better than expected, according to Citi. The Analyst Citi's Kate McShane upgraded Advance Auto Parts from Sell to Neutral. The Thesis Advance Auto Parts'...

Papa John’s International, Inc. (NASDAQ: PZZA) is executing new strategies to restore confidence among investors and customers after the departure of founder John Schnatter in a racism scandal, according to Stifel.  The Analyst Stifel analyst Chris O'Cull upgraded Papa John...

After a huge year in 2017, GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) stock has traded mostly sideways so far in 2018. But one analysts believes GW will soon return to its winning ways. The Analyst Stifel analyst Paul Matteis initiated coverage of GW Pharma with a Buy rating and $181 price target....

While 2018 has proven a difficult year for the toy industry, Hasbro, Inc. (NASDAQ: HAS) is well-positioned for a material fundamental recovery over the coming years, according to MKM Partners.  The Analyst MKM analyst Eric Handler upgraded Hasbro from Neutral to Buy with a price...

Exploration and production company Alta Mesa Resources Inc (NASDAQ: AMR) reported Tuesday with disappointing second-quarter results that sent shares sharply lower. The Analyst Imperial Capital analyst Irene Haas downgraded Alta Mesa from Outperform to In-Line and lowered the price target...

Fast casual restaurant chain Chipotle Mexican Grill, Inc. (NYSE: CMG) is undergoing a compelling earnings recovery story led by a new management team, according to Morgan Stanley.  The Analyst Morgan Stanley's John Glass upgraded Chipotle Mexican Grill from Equal-weight to...

Chubb Ltd (NYSE: CB) reported better than expected second-quarter earnings July 24 and declared quarterly dividend of 73 cents Aug. 9. It is payable on Oct. 12 to shareholders of record at the close on Sept. 21. The Analyst Deutsche Bank's Joshua Shanker downgraded Chubb from Hold to...

NVIDIA Corporation (NASDAQ: NVDA) is scheduled to report its second-quarter results after Thursday's close. Analysts, on average, expect EPS of $1.66 on revenue of $3.1 billion. The Analysts BMO Capital Markets' Ambrish Srivastava maintains a Market Perform rating on Nvidia with an...

Despite Marriott International Inc (NASDAQ: MAR)’s recent pullback, Raymond James considers the company “bruised, not broken.” The Analysts Raymond James analyst William Crow upgraded Marriott from Market Perform to Outperform and set a $140 price target. The Thesis The 7-...

The Coca-Cola Co (NYSE: KO)'s Powerade may never been able to match up with PepsiCo, Inc (NASDAQ: PEP)'s Gatorade, but Coca-Cola has a new plan to win the sports drink wars. What Happened? Coca-Cola announced Tuesday it has acquired a minority stake in the fast-growing sports...

Biotech Replimune Group, Inc. (NASDAQ: REPL), which conducts research and cancer treatment studies using oncolytic viruses, picked up a sell-side bull Tuesday. The Analyst BMO Capital Markets analyst Do Kim initiated coverage of Replimune Group with an Outperform rating and $31 price target. The...